These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2693361)

  • 21. [Clinical evaluation of cefotaxime in complicated urinary tract infections].
    Fujii K; Fujita K; Tsukada T; Nakahara M; Kanbayashi T; Aso Y
    Jpn J Antibiot; 1983 Aug; 36(8):2073-6. PubMed ID: 6317913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Richards DM; Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1984 Jun; 27(6):469-527. PubMed ID: 6329638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Minimal inhibitory and bactericidal concentrations of cefoperazone, cefotaxime, cefuroxime and cefalotin against 90 bacterial strains].
    Mascellino MT; Prignano G; Iegri F; Lorenzi A
    Boll Ist Sieroter Milan; 1982; 61(4):309-19. PubMed ID: 6100234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefotaxime (HR-756) in urinary tract infections.
    Paradisi F; Cristiano P; Mirone V; D'Armiento V; Iovene MR
    Chemotherapy; 1982; 28(1):64-9. PubMed ID: 6276110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cefotaxime in septicaemia and severe infections due to multiresistant Gram-negative bacilli (author's transl)].
    Dureux JB; Canton P; Roche G; Weber M; Gérard A
    Nouv Presse Med; 1981 Feb; 10(8):601-6. PubMed ID: 6259602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Moxalactam and cefotaxime--two new beta-lactam antibiotics compared with three well-known cephalosporins].
    Baumgärtner M; Dickgiesser N; Müller S; Wundt W
    Arzneimittelforschung; 1981; 31(10):1677-81. PubMed ID: 6274361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cefotaxime in urinary tract infections--comparative clinical studies with gentamicin and with cefoxitin.
    Ludwig G; Knebel L
    J Antimicrob Chemother; 1980 Sep; 6 Suppl A():207-11. PubMed ID: 6252158
    [No Abstract]   [Full Text] [Related]  

  • 28. [Spectrum of pathogens and resistance to antibiotics in urinary tract infections and the consequences for antibiotic treatment: study of urology inpatients with urinary tract infections (1994-2001)].
    Wagenlehner E; Niemetz A; Naber G
    Urologe A; 2003 Jan; 42(1):13-25. PubMed ID: 12574879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1983). I. Susceptibility distribution].
    Kosakai N; Igari J; Kumamoto Y; Sakai S; Shigeta S; Shiraiwa Y; Abe K; Tazaki H; Iri H; Uchida H
    Jpn J Antibiot; 1985 Aug; 38(8):2185-229. PubMed ID: 4079003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacteriological comparison of cefixime in patients with noncomplicated urinary tract infection in Spain. Preliminary results.
    García-Rodríguez JA
    Chemotherapy; 1998 Sep; 44 Suppl 1():28-30. PubMed ID: 9797421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.
    Wagenlehner FM; Lehn N; Witte W; Naber KG
    Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
    Rossi B; Soubirou JF; Chau F; Massias L; Dion S; Lepeule R; Fantin B; Lefort A
    Antimicrob Agents Chemother; 2016 Jan; 60(1):424-30. PubMed ID: 26525800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibiotic treatment of urinary tract infections.
    Kumazawa J; Momose S; Nakamuta S
    Clin Ther; 1981; 4 Suppl A():18-24. PubMed ID: 6275995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefotaxime: clinical and bacteriologic evaluation.
    Saroglou G; Paniara-Volika O; Sima A; Koltsida K; Rokas S; Kontomichalou P
    Clin Ther; 1981; 4(3):201-11. PubMed ID: 6272994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of cefotaxime against enterococci.
    Moellering RC; Eliopoulos GM
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):85S-90S. PubMed ID: 6086221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
    Scully BE; Neu HC
    Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin-resistant Enterococcus spp (VRE): a single-center university hospital experience.
    Shah KJ; Cherabuddi K; Shultz J; Borgert S; Ramphal R; Klinker KP
    Int J Antimicrob Agents; 2018 Jan; 51(1):57-61. PubMed ID: 28666756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms.
    Francke EL; Neu HC
    Am J Med; 1981 Sep; 71(3):435-42. PubMed ID: 6269426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I; Warren C; Shannon K; King A; Hanslo D
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.